Comparison of autophagy inducibility in various tyrosine kinase inhibitors and their enhanced cytotoxicity via inhibition of autophagy in cancer cells in combined treatment with azithromycin

Tyrosine kinase inhibitors (TKIs) induce autophagy in many types of cancer cells. We previously reported that gefitinib (GEF) and imatinib (IMA) induce autophagy in epidermal growth factor receptor (EGFR) knock-out A549 and non-BCR-ABL-expressing leukemia cell lines, respectively. This evidence sugg...

Full description

Bibliographic Details
Main Authors: Hideki Tanaka, Hirotsugu Hino, Shota Moriya, Hiromi Kazama, Masaya Miyazaki, Naoharu Takano, Masaki Hiramoto, Kiyoaki Tsukahara, Keisuke Miyazawa
Format: Article
Language:English
Published: Elsevier 2020-07-01
Series:Biochemistry and Biophysics Reports
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2405580820300595
id doaj-c639655190624e29aa720337aaa658e3
record_format Article
spelling doaj-c639655190624e29aa720337aaa658e32020-11-25T03:03:50ZengElsevierBiochemistry and Biophysics Reports2405-58082020-07-0122Comparison of autophagy inducibility in various tyrosine kinase inhibitors and their enhanced cytotoxicity via inhibition of autophagy in cancer cells in combined treatment with azithromycinHideki Tanaka0Hirotsugu Hino1Shota Moriya2Hiromi Kazama3Masaya Miyazaki4Naoharu Takano5Masaki Hiramoto6Kiyoaki Tsukahara7Keisuke Miyazawa8Department of Otolaryngology (Head and Neck Surgery), Tokyo Medical University Hospital, 6-7-1, Nishishinjuku, Shinjuku-ku, Tokyo, 160-0023, JapanDepartment of Biochemistry, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo, 160-8402, JapanDepartment of Biochemistry, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo, 160-8402, JapanDepartment of Biochemistry, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo, 160-8402, JapanDepartment of Biochemistry, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo, 160-8402, JapanDepartment of Biochemistry, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo, 160-8402, JapanDepartment of Biochemistry, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo, 160-8402, JapanDepartment of Otolaryngology (Head and Neck Surgery), Tokyo Medical University Hospital, 6-7-1, Nishishinjuku, Shinjuku-ku, Tokyo, 160-0023, JapanDepartment of Biochemistry, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo, 160-8402, Japan; Corresponding author.Tyrosine kinase inhibitors (TKIs) induce autophagy in many types of cancer cells. We previously reported that gefitinib (GEF) and imatinib (IMA) induce autophagy in epidermal growth factor receptor (EGFR) knock-out A549 and non-BCR-ABL-expressing leukemia cell lines, respectively. This evidence suggests that TKI-induced autophagy is independent of the original target molecules. The present study compared the autophagy-inducing abilities of various TKIs, regardless of their targets, by quantitative autophagy flux assay. We established stable clones expressing the GFP-LC3-mCherry-LC3ΔG plasmid in A549, PC-9, and CAL 27 cell lines and assessed autophagy inducibility by monitoring the fluorescent ratios of GFP-LC3 to mCherry-LC3ΔG using an IncuCyte live cell imaging system during exposure to TKIs viz; GEF, osimertinib (OSI), lapatinib (LAP), lenvatinib (LEN), sorafenib (SOR), IMA, dasatinib (DAS), and tivantinib (TIV). Among these TKIs, DAS, GEF, and SOR exhibited prominent autophagy induction in A549 and PC-9 cells. In CAL 27 cells, IMA, SOR, and LEN, but not GEF, TIV, or OSI, exhibited autophagy induction. In the presence of azithromycin (AZM), which showed an inhibitory effect on autophagy flux, TKIs with prominent autophagy inducibility exhibited enhanced cytotoxicity via non-apoptotic cell death relative to effects of TKI alone. Therefore, autophagy inducibility of TKIs differed in the context of cancer cells. However, once induced, they appeared to have cytoprotective functions. Thus, blocking TKI-induced autophagy with AZM may improve the therapeutic effect of TKIs in cancer cells.http://www.sciencedirect.com/science/article/pii/S2405580820300595Tyrosine kinase inhibitorAutophagyMacrolide antibioticsCancer
collection DOAJ
language English
format Article
sources DOAJ
author Hideki Tanaka
Hirotsugu Hino
Shota Moriya
Hiromi Kazama
Masaya Miyazaki
Naoharu Takano
Masaki Hiramoto
Kiyoaki Tsukahara
Keisuke Miyazawa
spellingShingle Hideki Tanaka
Hirotsugu Hino
Shota Moriya
Hiromi Kazama
Masaya Miyazaki
Naoharu Takano
Masaki Hiramoto
Kiyoaki Tsukahara
Keisuke Miyazawa
Comparison of autophagy inducibility in various tyrosine kinase inhibitors and their enhanced cytotoxicity via inhibition of autophagy in cancer cells in combined treatment with azithromycin
Biochemistry and Biophysics Reports
Tyrosine kinase inhibitor
Autophagy
Macrolide antibiotics
Cancer
author_facet Hideki Tanaka
Hirotsugu Hino
Shota Moriya
Hiromi Kazama
Masaya Miyazaki
Naoharu Takano
Masaki Hiramoto
Kiyoaki Tsukahara
Keisuke Miyazawa
author_sort Hideki Tanaka
title Comparison of autophagy inducibility in various tyrosine kinase inhibitors and their enhanced cytotoxicity via inhibition of autophagy in cancer cells in combined treatment with azithromycin
title_short Comparison of autophagy inducibility in various tyrosine kinase inhibitors and their enhanced cytotoxicity via inhibition of autophagy in cancer cells in combined treatment with azithromycin
title_full Comparison of autophagy inducibility in various tyrosine kinase inhibitors and their enhanced cytotoxicity via inhibition of autophagy in cancer cells in combined treatment with azithromycin
title_fullStr Comparison of autophagy inducibility in various tyrosine kinase inhibitors and their enhanced cytotoxicity via inhibition of autophagy in cancer cells in combined treatment with azithromycin
title_full_unstemmed Comparison of autophagy inducibility in various tyrosine kinase inhibitors and their enhanced cytotoxicity via inhibition of autophagy in cancer cells in combined treatment with azithromycin
title_sort comparison of autophagy inducibility in various tyrosine kinase inhibitors and their enhanced cytotoxicity via inhibition of autophagy in cancer cells in combined treatment with azithromycin
publisher Elsevier
series Biochemistry and Biophysics Reports
issn 2405-5808
publishDate 2020-07-01
description Tyrosine kinase inhibitors (TKIs) induce autophagy in many types of cancer cells. We previously reported that gefitinib (GEF) and imatinib (IMA) induce autophagy in epidermal growth factor receptor (EGFR) knock-out A549 and non-BCR-ABL-expressing leukemia cell lines, respectively. This evidence suggests that TKI-induced autophagy is independent of the original target molecules. The present study compared the autophagy-inducing abilities of various TKIs, regardless of their targets, by quantitative autophagy flux assay. We established stable clones expressing the GFP-LC3-mCherry-LC3ΔG plasmid in A549, PC-9, and CAL 27 cell lines and assessed autophagy inducibility by monitoring the fluorescent ratios of GFP-LC3 to mCherry-LC3ΔG using an IncuCyte live cell imaging system during exposure to TKIs viz; GEF, osimertinib (OSI), lapatinib (LAP), lenvatinib (LEN), sorafenib (SOR), IMA, dasatinib (DAS), and tivantinib (TIV). Among these TKIs, DAS, GEF, and SOR exhibited prominent autophagy induction in A549 and PC-9 cells. In CAL 27 cells, IMA, SOR, and LEN, but not GEF, TIV, or OSI, exhibited autophagy induction. In the presence of azithromycin (AZM), which showed an inhibitory effect on autophagy flux, TKIs with prominent autophagy inducibility exhibited enhanced cytotoxicity via non-apoptotic cell death relative to effects of TKI alone. Therefore, autophagy inducibility of TKIs differed in the context of cancer cells. However, once induced, they appeared to have cytoprotective functions. Thus, blocking TKI-induced autophagy with AZM may improve the therapeutic effect of TKIs in cancer cells.
topic Tyrosine kinase inhibitor
Autophagy
Macrolide antibiotics
Cancer
url http://www.sciencedirect.com/science/article/pii/S2405580820300595
work_keys_str_mv AT hidekitanaka comparisonofautophagyinducibilityinvarioustyrosinekinaseinhibitorsandtheirenhancedcytotoxicityviainhibitionofautophagyincancercellsincombinedtreatmentwithazithromycin
AT hirotsuguhino comparisonofautophagyinducibilityinvarioustyrosinekinaseinhibitorsandtheirenhancedcytotoxicityviainhibitionofautophagyincancercellsincombinedtreatmentwithazithromycin
AT shotamoriya comparisonofautophagyinducibilityinvarioustyrosinekinaseinhibitorsandtheirenhancedcytotoxicityviainhibitionofautophagyincancercellsincombinedtreatmentwithazithromycin
AT hiromikazama comparisonofautophagyinducibilityinvarioustyrosinekinaseinhibitorsandtheirenhancedcytotoxicityviainhibitionofautophagyincancercellsincombinedtreatmentwithazithromycin
AT masayamiyazaki comparisonofautophagyinducibilityinvarioustyrosinekinaseinhibitorsandtheirenhancedcytotoxicityviainhibitionofautophagyincancercellsincombinedtreatmentwithazithromycin
AT naoharutakano comparisonofautophagyinducibilityinvarioustyrosinekinaseinhibitorsandtheirenhancedcytotoxicityviainhibitionofautophagyincancercellsincombinedtreatmentwithazithromycin
AT masakihiramoto comparisonofautophagyinducibilityinvarioustyrosinekinaseinhibitorsandtheirenhancedcytotoxicityviainhibitionofautophagyincancercellsincombinedtreatmentwithazithromycin
AT kiyoakitsukahara comparisonofautophagyinducibilityinvarioustyrosinekinaseinhibitorsandtheirenhancedcytotoxicityviainhibitionofautophagyincancercellsincombinedtreatmentwithazithromycin
AT keisukemiyazawa comparisonofautophagyinducibilityinvarioustyrosinekinaseinhibitorsandtheirenhancedcytotoxicityviainhibitionofautophagyincancercellsincombinedtreatmentwithazithromycin
_version_ 1724684238914060288